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c-myc Protooncogene Expression in Mouse
Erythroleukemia Cells
by Herbert M. Lachman*
Murine erythroleukemia (MEL) cells are erythroid progenitors whose program oferythroid differentiation
has been interrupted by transformation with the Friend virus complex. As a result ofthe ability ofcertain
chemicals such as dimethylsulfoxide (DMSO) to induce terminal erythroid differentiation, the cells have been
used as a model forunderstanding the molecular basis ofcellular differentiation. Recent work on MEL cells
as well as other differentiating systems indicates that expression ofcellular protooncogenes is implicated in
chemically mediated differentiation. In MEL cells the expression ofthe c-mycprotooncogene undergoes un-
usual biphasic changes following inducertreatment. Levels ofc-myc mRNA decrease 10- to 20-fold between
1 and 2 hr and are then reexpressed between 12 and 24 hr. These changes occur as a result ofcomplex tran-
scriptional andposttranscriptional regulatory events. Recent DNAtransfection experiments, in which MEL
cells were transfected with mycexpression vectors, indicate thatboth the early decrease in c-mycexpression
and its subsequent reexpression are important events in the differentiation pathway. The work on MEL cells,
as well as on other models ofdifferentiation, is directed at understanding the molecular basis of leukemo-
genic transformation and cellular differentiation. The ability ofc-myc, as well as other protooncogenes, to
influence both ofthese events indicates that cellular protooncogenes play a central role in their regulation.
Introduction
We have been interested in the role ofprotooncogenes,
in particular the c-myc gene, in the differentiation of
mouse erythroleukemia (MEL) cells. MEL cells are ery-
throid precursors that are arrested at an early stage of
differentiation as a result of viral transformation. They
were isolated by the late Charlotte Friend from mice in-
fected with avirus derived from acell-free tumor extract
(1). Initially, morphological analysis suggested that the
cells were either a myeloid or lymphoid leukemia line.
However, the discovery that MEL cells contain hemo-
globin suggested that they were erythroid in origin (2).
In 1971, Dr. Friend and her colleagues at the Mt. Sinai
School ofMedicine made an important observation. Dur-
ing attempts at superinfecting the cells using dimethyl-
sulfoxide (DMSO), they discovered that more than 95% of
the cells stainedpositively forhemoglobin withbenzidine
reagent. Bycontrast, lessthan 1% ofuntreatedMEL cells
contain enough hemoglobin to become benzidine positive
(3). Perhaps a more important observation was that
DMSO-treated cells had reduced leukemogenic potential.
Thus DMSO treatment results in the conversion of ery-
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throleukemia cells, that areeasilypassagedbetween suit-
able mouse strains, to cells that exhibit a terminally
differentiated phenotype. Since these observations were
made, the MEL cell system has been used as amodelfor
understanding the molecular basis of leukemic trans-
formation and cellular differentiation.
Although it is not the purpose ofthis review to explore
inmuch depththe hundreds ofpapersthat havebeenpub-
lished on this system, some important features that
should serve as abackgroundforthemajorconcern ofthis
paper, the role of the c-myc protooncogene in MEL cell
differentiation, will be mentioned. For more specific de-
tails concerningbiochemical events during differentiation
andthe nature ofthe various chemical agents used to in-
duce differentiation, the reader is referred to the excel-
lent Rifkind and Marks review (4).
Before discussing the role ofcellular protooncogenes in
differentiation, it is important to understand the basis of
viral transformation ofMEL cells. The Friend viral com-
plexis composed oftworetroviruses: areplication defec-
tive, spleen-focus-forming virus(SFFV)and areplication-
competent murine leukemia virus(MuLV)(5,6). Although
the Friend virus complex is capable ofrapidly inducing
leukemic transformation, it differs from other acutely
transforming retroviruses in that neither SFFV nor
MuLV contains transduced, cellular-derived oncogenes.H. M. LACHMAN
Thetransforming abilityofSFFVappearstoreside inthe
env gene, which encodes a glycoprotein, gp55, found on
the surface ofinfected cells. Mutations in gp55 are capa-
ble ofabolishing the ability of SFFV to induce erythro-
leukemia (7,8). It is thought thattheglycoproteinmaybe
involved in sending a constitutive growth signal in in-
fected cells (9), perhaps similar to retroviruses that con-
tain transduced cellular derived oncogenes encoding
growth factors orgrowth factorreceptors, such as simian
sarcoma virus (10,11) or avian erythroblastosis virus
(12,13). The MuLV functions as a replication-competent
helper virus but may also be involved in pathogenicity
since itis capable, on its own, ofinducingerythroidleuke-
mias after a relatively prolonged latent period (14).
Presumably, MuLV induces malignant transformation by
proviral insertional mutagenesis of a cellular oncogene,
similarto avianleukosis virus(15). Since SFFV also inte-
grates as a provirus (16), it could function in this way as
well. The cellular genomic targets of these integration
events have not yet been identified.
Concept of Commitment
Typically when MEL cells are induced to differentiate,
cells are treated with hexamethylene bisacetamide
(HMBA) or DMSO for 5 days during which an arrest in
cellgrowth andthe accumulation oflarge amounts ofhe-
moglobin are observed(4,17). However, 5 days ofcontinu-
ous inducer treatment is not needed for the cells to
differentiate. Ifaculture istreatedwithinducerfor a cer-
tainperiodoftime, thenplatedin semisolid medium inthe
absence of inducer, individual cells will multiply into a
colony whosephenotype reflects the capacity ofthe par-
entcell to differentiate. WhenMELcells aretreatedwith
inducer for less than 10 hr, then plated without inducer,
100% ofthe colonies will be composed ofbenzidine nega-
tive, undifferentiated cells. However, after 10 to 12 hr of
inducertreatment, a smallpercentage ofcellsgives rise,
after 5 days ofgrowth, to colonies of cells that are fully
hemoglobinized and differentiated. The parent of the
hemoglobinized colonyofcells is said to be committed to
erythroid differentiation (18,19). After 12 hr, an increas-
ingpercentage ofcells becomes committed until approx-
imately48 hrwhenvirtually 100%ofthe cells develop into
differentiated colonies. Two importantfeatures ofa com-
mitted cellinclude itsrestriction to aboutfourorfive cell
divisions, whereas uncommitted cells will continue to
proliferate indefinitely, and the irreversibility ofthe com-
mitment program (18).
There are many intriguing questions one can ask re-
gardingcommitmentofMEL cellsto differentiate. Forex-
ample, what determines the length ofthe latent period,
which lasts for approximately 10 hr after inducer is
added, before committed cells canbe detected? What are
the changes ingene expressionthat occur, during the la-
tent and commitment periods, and how are these genes
regulated? And finally, why do MEL cells become com-
mitted asynchronously such that some cellsrequire 12 hr
and others 48 hr ofinducer treatment? It has been sug-
gested that the commitmentprogram develops stochasti-
cally with the probability that acell will become commit-
ted increasing with prolonged inducer treatment (18).
Data will be presented later in this review that demon-
strate that the expression of the c-myc protooncogene
could be involved in the decision ofcells to become com-
mitted.
Early and Late Changes during the
Differentiation Program
Rifkind and Marks have suggested that the changes
that occur in MEL cells during chemically induced
differentiation could be separated into early and late
events (4), a distinction that is useful in presenting the
differentiation process. A brief summary ofsome ofthe
early changes that occurin inducertreated MEL cells in-
clude: increased Ca2+ uptake (20) and cAMP levels (21),
a decrease in phosphatidylinositol turnover (22), and in-
creased expression ofsome erythroid-associated proteins
such as spectrin, glycophorin and histone Hio (23-25).
The importance ofthe changes in Ca2" are supported
by thefindings that treatment ofMEL cells with a Ca2+
ionophore increases the rate of inducer-mediated entry
into a commitment program, whereas EGTAinhibits en-
try (26). The decrease in phosphotidylinositol turnover
also appears to be an early critical event. The products
ofphosphotidylinositol breakdown, diacylglycerol (DAG)
and inositol triphosphate (IP3) are important intracellu-
larmediators ofthegrowth response. Proteinkinase C is
the target of DAG, whereas IP3 mobilizes intracellular
Ca2+ (27-29). The importance of the early decrease in
DAG in the differentiation scheme is supported by the
findingthattreatmentofMEL cellswith DAGanalogues
inhibits differentiation (22). These early changes occur
duringthe latentperiod ofinducertreatment, before com-
mitted cells can be detected.
Late events in the differentiationprocessinclude the ac-
cumulation ofglobin mRNA andprotein(30-32), enzymes
involved in heme synthesis (33), and band 3, the trans-
membrane anion exchanger (34). Also occurring during
thistime are the chromatin andcytoskeletal changes that
are associatedwithterminalerythroiddifferentiation(35).
The increase in globin mRNA is due largely to an in-
crease inglobin gene transcription(36,37)which appears
to be correlated with achange inglobin chromatin struc-
ture manifestedby the appearance ofDNAse 1 hypersen-
sitive sites in the Pmajorgene locus(38). The increase in
band 3 expression also results from an increase in band
3 gene transcription (33).
Arbitrarily separatingthe early andlate events in time
is a Gl prolongation in which cells accumulate in the G,
phase of the cell cycle between 12 and 24 hr of inducer
treatment (39). Although the timing ofthis event is cor-
related with the ability to detect the earliest committed
cells, the importance of G1 prolongation in the commit-
ment process is not known.
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c-myc Expression during MEL Cell
Differentiation
The earliest direct evidence that oncogenes couldbe in-
volved in leukemic transformation and cellular differen-
tiation is from work with acutely transforming
retroviruses containingviral oncogenes. A temperature-
sensitive mutant of E26 leukemia virus, which contains
the v-myb oncogene, induces leukemia at thepermissive
temperature. Following a switch to the nonpermissive
temperature, infected cells spontaneously differentiate
(40). This suggests that the expression of v-myb at the
permissive temperature could inhibit the differentiation
process andits inactivation at the nonpermissive temper-
ature could switch the cells to a differentiatedphenotype.
Anotherfindingthat suggests that oncogenes have arole
in differentiation is the observation that DMSO induction
ofthe human promyelocytic leukemia cell line HL-60 to
mature granulocytes is accompanied by alarge decrease
in c-myc expression (41,42). Similarly retinoic acid induc-
tion ofF9 teratocarcinoma cells leads to alarge decrease
in c-myc expression (43). These findings suggest an asso-
ciation between the differentiation ofcells with adecrease
in the expression of certain protooncogenes. In other
cases, the expression of oncogenes appears to promote
differentiation. Forexample, PC-12 cells infectedwith ras-
containing retroviruses or microinjected with a ras onco-
genic protein spontaneously undergo neuronal differen-
tiation, independent of nerve growth factor (44,45). Simi-
larly, F9 teratocarcinoma cells transfected with the
adenovirus EIA gene also undergo spontaneous differen-
tiation (46).
Ourwork on the role ofoncogenes in MEL cell differen-
tiation beganby screening MEL cell RNAwith avariety
of oncogene probes, which revealed that c-myc mRNA
was easily detected in uninduced MEL cells and
decreased about 10-fold in terminally differentiated cells.
Although this result was similar to the findings in HL-60
cells, it was notterriblyrevealingsince the level ofmany
mRNAs decrease in terminally differentiated MEL cells.
As we were interested in the relationship between com-
mitment and the expression of oncogenes, we examined
more carefully the expression of c-myc during the latent
and commitment periods ofinducer treatment. We found
a curious pattern of expression. Within 2 hr of DMSO
treatment there is a 10- to 20-fold decrease in c-myc
mRNA. The level remains low until 12 to 24 hr, when the
mRNA is transiently reexpressed to the level found in
uninduced cells. Thereafter, c-myc mRNA levels decrease
again as the cells differentiate (47)(Fig. 1). Aparticularly
striking aspect ofthis observation was thetemporal rela-
tionship between the early changes in c-myc mRNA
levels and the detection of the earliest committed cells.
Itled us to consider thepossibilitythatthe changes in c-
myc expression could be important in the commitment
process. The changes in c-myc mRNA we observed ini-
tially appeared to be specific for this RNA in MEL cells
and not due to ageneral effect ofDMSO on RNA expres-
sion in MEL and othercells. Forexample, DMSO doesnot
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FIGURE 1. Changes in c-myc mRNA during inducer treatment. Ibtal
cellular RNA extracted from DMSO-treated cells was separated by
gel electrophoresis, transferred to nitrocellulose filters, andhybridized
with radiolabeled c-myc, f3-globin, and P-actin-specific probes
(Northern filter hybridization).
induce similar c-myc mRNA changes in a lymphoid line
that does not differentiate in response to DMSO. Also, the
level ofpglobin, actin, andhistone H3mRNAs didnotun-
dergo similar changes in MEL cells (47). Recently, how-
ever, we have detected some RNAs whose expression is
similarto c-myc, so the effectis not as specific aswe once
thought. Biphasic c-myc expression occurs with otherin-
ducers of differentiation such as HMBA and hypoxan-
thine, although the kinetics of the changes may differ
among different agents (48).
In order to determine whetherthe changes in c-myc ex-
pression are important for commitment and differentia-
tion, we studied the effects ofvarious inhibitors ofMEL
cell differentiation. Wefound that one potent inhibitor, cy-
cloheximide, which inhibits de novo protein synthesis,
completely blocks the reexpression ofc-myc mRNAthat
occurs between 12 and 24 hr of inducer treatment, sug-
gesting a correlation between inhibition ofdifferentiation
and the reexpression of c-myc. Baseline levels of c-myc
mRNA in uninduced cells are unaffected by cyclohexi-
mide treatment. Two other inhibitors of differentiation,
EGTAandphorbol esters, also affectthe reexpression of
c-myc mRNA, but not to the extent of cycloheximide.
These agents delaymycreexpression suchthattheusual
peak, which occurs at 16 hr, is not detected until approx-
163H. M. LACHMAN
imately 24 hr. However, two other inhibitors ofdifferen-
tiation, growth in 1% fetal calfserum and dexamethasone,
have no effect on the pattern ofc-myc reexpression (un-
published observations). Thus, the changes in c-myc
mRNA expression following the addition ofinducers of
differentiation may be necessary but not sufficient for
commitment to occur.
myc Expression in the Cell Cycle
The timing of c-myc reexpression coincides with the
transient accumulation ofcells in the Gi phase ofthe cell
cycle that occurs between 12 and 24 hr ofinducer treat-
ment (39,49). It hasbeen suggestedthat the Gl arrest of
cells couldbe involved in commitment to differentiate, al-
though the findingthatthe inducers hypoxanthine and ac-
tinomycin D do not prolong the Gl phase argues some-
what against this hypothesis (50). Another finding
suggesting that the cell cycle may be important in com-
mitment to differentiate is that cells synchronized with
respect to the cell cycle become committed at different
rates (51). There have been conflicting reports regarding
the role of DNA synthesis in MEL cell differentiation.
Several groups have reported that DMSO must be pres-
ent for at least one round ofDNA synthesis in order for
differentiation to occur (52,53). However, Leder et al.
showed thatcellstreatedwithbutyric acidcould differen-
tiate in the absence ofcell division(54), and Levenson et
al. found that DNA synthesis is not requiredfor commit-
ment(55). Inorderto study the relationshipsbetween the
cell cycle, myc expression, and itsrelationship to commit-
ment, we measured c-myc mRNA levels in cells syn-
chronized by centrifugal elutriation. In this technique,
cells are separated into differentcell cycle fractionsbased
on their size, which is correlated with DNA content. We
separated alogarithmic culture ofuninduced MEL cells
into cell-cycle-specific fractions, isolated total cellular
RNA, and measured the relative level of c-myc mRNA
ineachfractionbyNorthernfilterhybridization. Asa con-
trol for the quality ofthe elutriation, we also measured
histone H3 mRNA levels, because previous studies had
shown that H3 expression inMEL cellsprimarily occurs
in S phase cells (56). The analysis revealed that c-myc
mRNAlevels varied less than 2-fold across the cell cycle,
in contrast to H3 mRNA inwhich there was8- to 10-fold
more H3 mRNA in S compared to Gi cells (48) (Fig. 2).
These data agreed with the findings of several groups
that expression ofc-myc mRNA and protein in replicat-
ing cells is constitutive across the cell cycle (57,58).
A different pattern of c-myc expression is found in
inducer-treated cells. MEL cells were separated into cell-
cycle-specific fractions following treatment with hypo-
xanthine for 7 hr, a period of time sufficient for c-myc
mRNAlevels to decrease thenreaccumulate in response
to this particular inducer. In contrast to the absence of
significant variation in c-myc mRNAlevels acrossthe cell
cycle in uninduced cells, we detected 8-fold more c-myc
mRNAin cellsinGi comparedwithcellsinS(48)(Fig. 2).
The change in the cell cycle distribution of c-myc
mRNA occurswithout any change in H3 mRNA expres-
sion. The reexpression ofc-mycmRNAin Gi cellsfollow-
inginducertreatmentwas confirmedusingadifferentex-
perimental approach with another inducer. Uninduced
cells were separated intoGi, S, and G2fractions. The syn-
chronized populations of cells were then treated with
DMSO andaliquots were removedevery4hrfortotal cel-
lular RNAextraction. We also followedthe cells' positions
in the cell cycle by flow microfluorometry analysis of
propidium iodide-stained cells. We found that the timing
ofc-myc mRNAreexpression was dependent on the cells'
positions in the cell cycle when first exposed to inducer
(48) (Fig. 3). For example, cells that were in S when first
exposed to DMSO reexpress c-myc mRNA after only 8
hr, coincidingwith the time ofmaximum accumulation of
these cells in G1. Cells that were in G, when DMSO was
added reexpress c-myc mRNA between 12 and 16 hr, a
time that corresponds to an accumulation ofthe cells in
the next G, phase. Finally, cells that started in G2 reex-
press c-mycmRNAbetween 16and24hr, aperiodoftime
correspondingto the passage ofthe cells through a com-
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FIGURE 2. Change in cell cycle distribution of c-myc mRNA during
hypoxanthine induction. (A) UninducedMELcells wereseparatedinto
cell cycle fractions by centrifugal elutriation. The C-values at the
bottom reflect the average DNA content of cells in each fraction
determined by flow microfluorometry analysis ofpropidium iodide
stained cells. A C-value of2reflects thediploid content ofDNA(cells
inGOorGl); aC-value of4isfoundincellsinG2JM. Ibtalcellular RNA
was extracted from each fraction and anlyzed by Northern filter
hybridization. The 10-foldincrease in H3 histone mRNA in mid-S(C
= 2.5-3.1), determined by densitometric analysis ofthe hybridizing
bands, isconsistent withpreviousfindingsconcerningH3expression
inthe cellcycle. In contrast, c-mycmRNAlevels varyless than 2-fold
across the cycle. (B) Cells were also separated into cell cycle speciflc
fractionsfollowing 7 hr oftreatment withthe inducerhypoxanthine.
During this time, c-myc mRNA levels have decreased and then are
reexpressed (upperpanel). Northern filterhybridization revealed that
while H3mRNAispredominantly found in mid-S cells(C = 2.4-3.0)
as in uninduced cells, 8-fold more c-myc mRNA is now found in GI
cells compared with cells in S.
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FIGURE 3. Timing of c-myc mRNA reexpression depends on the cell's
position in the cell cycle before inducer treatment. Uninduced cells
were synchronized intoG1, S, and G2 cellsby centrifugal elutriation.
The cells were thentreated with theinducerHMBAandtotalcellular
RNA wasextracted every4 hr. The cell'sprogression throughthe cell
cycle wasfollowedbyflowmicrofluorometry analysis (data not shown).
C-myc reexpression occurs at 8, 12-16, and 16 hrfor cells starting in
S, GI, and G2, respectively, corresponding to the time that the cells
accumulate in the G1 phase ofthe cell cycle.
plete cell cycle, then back to Gi. The inability ofG2 cells
to reexpress c-myc in the first G1, after 4 hr of DMSO
treatment, mayreflect alatentperiod before reexpression
can occur. These data support the hypothesis that the
reexpression of myc mRNA occurs primarily in G, cells
and demonstrates that the gradual reaccumulation of c-
myc mRNA between 12 and24 hr ofDMSO treatment is
apparently due to the different times nonsynchronous
populations of MEL cells arrest in GI and reexpress c-
myc mRNA.
The consequence ofthe change in expression of c-myc
with respect to the cell cycle is not known. The coinci-
dental timing of this change with the detection of the
earliest committed cells could indicate that the decrease
in c-myc expression in S cells or the increase in GI cells
that occur during inducer treatment, may be important
signals in commitment to differentiate.
Effect of Transfected myc
Expression Vectors on Commitment
The most direct experimental approach to determine
the effect of myc on commitment to differentiate is to
transfect MEL cells with a myc recombinant vector
whose expression is not influenced by the factors that
presumably regulate endogenous myc expression in
differentiating MEL cells. We constructed a myc expres-
sion vector which we thought satisfied all the require-
ments for autonomous regulation. A 1.36 kb Xhol frag-
ment from a c-myc, c-DNA clone (59), which contains the
myc coding sequences and minimal 5' and 3' noncoding
information, was cloned near apromoter from the mouse
metallothionein (MT)1 gene. The 5'noncoding exon which
contains the c-myc promoters, and an AU rich 3' end,
which maybe involved in c-myc mRNAinstability, are al-
most entirely omitted from the construct (60,61). The
MT-1 promoter is capable ofdrivingthe expression ofhet-
erologous genes, following treatment with heavy metals
(62). Prior to the transfection we found that endogenous
MT-1 is induced following treatment with cadmium sul-
fate, at concentrations that did not inhibit MEL cell
differentiation. The stage seemed set for a well thought
out transfection experiment. However, the biology ofthe
system didnotfollowthe planswe madeforit. Although
we obtained 9 transfectant clones that expressed a chi-
meric MT-myc mRNA, only two clones were inducible
with cadmium sulfate. Unfortunately, the concentration
necessary to induce MT-myc expression inhibited
differentiation inparental cells andtherefore could notbe
used to study the effect of myc expression on commit-
ment. The other 7 clones constitutively express MT-myc
mRNA in uninduced cells.
We next studied the effect ofHMBA treatment on MT-
myc expression and found that expression of MT-myc
mimicked the biphasic changes that occur in endogenous
c-myc mRNA (Fig. 4). A chimeric myc gene was con-
structed in which c-myc coding exons were cloned near
the metallothionein I (MT-1) promoter. The resultant
recombinant plasmid, pMT-myc was transfected into
MEL with pSV2neo and selected in G 418. Total cellular
RNAwas extracted atvarious intervals ofHMBA treat-
ment and assayed using an RNAse protection assay.
There is a decrease inthelevel ofMT-mycmRNAwithin
2 hr of inducer treatment, followed by its reexpression
(63). Fortunately there was a critical difference between
MT-myc and c-myc reexpressionthatwewere able to ex-
ploit. Whereas c-myc mRNA is reexpressed between 12
and 24 hr ofHMBA treatment, with apeak at 16 hr, MT-
myc mRNAis reexpressed between 4 and 8 hr. We were
therefore able to determine the effect ofearlymyc reex-
pression on commitment. Indeed, we found that 6/7 MT-
myc transfectant clones that reexpress MT-myc mRNA
between 4 and 8 hr have a more rapid rate ofentry into
the commitment program compared with parental cells
and control transfectant lines (Fig. 4). This suggests that
the rate ofentryinto acommitmentprogram is correlated
withthetimingofmycreexpression. This hypothesis was
supported when c-myc mRNA reexpression was meas-
ured in spontaneously derived, rapidly committing sub-
clones ofthe parent MEL cell line, DS19, which commit
asrapidly as MT-myc transfectant lines andreexpress c-
myc mRNA early, between 8 and 12 hr. In addition, we
isolatedlines that exhibited adelay in c-myc mRNAreex-
pression and were found to commit more slowly than
parental cells (63).
Because MT-myc expression isnot constitutive during
inducer treatment, we were not able to determine the ef-
fect ofthe early decline on commitment. However, almost
simultaneously with the publication of our transfection
results, threegroupsreported the successful transfection
ofMEL cells with recombinant myc expression vectors
whose expression is constitutive during inducer treat-
ment (64-66). These groups found that constitutive ex-
pression of chimeric myc mRNAs inhibits MEL cell
differentiation. These data, in combination with the MT-
myc transfectant results therefore suggest that both
phases of the changes in c-myc expression, transient
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FIGURE 4. Effect of transfected myc sequences on MEL cell
commitment. (A) C-mycmRNAhastwoprotectedfragments seen at
the top ofthegel. There are also two subbands generatedby RNAse
treatment that have not been fully characterized. In addition to the
c-myc protected fragments, the MT-myc transfectant line shown on
the right also contains bands corresponding to MT-myc mRNA. Note
that the decline and reexpression of MT-myc mRNA occur more
rapidly than c-myc mRNA. (B) Commitment assays were performed
by treating cells with HMBA for 12-42 hr with subsequent plating
in methycellulose without inducer. Colonies were scored for the
presence (committed) or absence (uncommitted) ofhemoglobin after
5 days inmethylcellulose. Thethickline is atypical commitment curve
for the parent cell line, DS19. The thin lines represent analysis of 7
MT-myc transfectant clones. Control transfectant lines commit with
similar kinetics as the parent in over 80% ofexamplesanalyzed (data
not shown).
downregulation, and myc reexpression are important
events in determining the differentiated phenotype of
MEL cells. Presumably, these effects are due to the in-
fluence ofmycprotein on the expression ofcommitment
and differentiation specific genes.
Regulation of c-myc Expression
Since, DNA transfection experiments indicated that
changes in c-myc expression have an effect on MEL cell
differentiation, we decided to carefully investigate the
mechanisms responsible for the changes. In collaboration
with Ken Marcu and Alain Nepveu at Stony Brook, we
measured the transcriptional and posttranscriptional
componentsregulatingc-mycmRNAlevels inMEL cells.
Measuringtranscriptional activity is arelatively routine
procedure in which isolated nuclei are labeled with 32p-
uridine triphosphate (UTP) in vitro. The labeled RNAs
reflect transcriptional elongation ofpreviously initiated
transcription units (67). Labeled RNA is recovered and
annealed to membrane-bound DNA probes containing
genes ofinterest. The assay hasbeen complicatedfollow-
ing the discovery by Bentley and Groudine that c-myc
genetranscription couldbe regulated at the level oftrans-
cription elongation (68). The c-myc gene is made up of
three exons in which exons 2 and 3 encode myc protein
(59). Thefirst exon is along, 5'untranslated sequence that
contains two transcriptional start sites.
Bentley and Groudine found a molar excess of exon 1
transcription comparedwith transcription inexons2 and
3, resulting from an intragenic block in RNA elongation
near the exon 1 - intron 1 boundary, an effect also called
transcriptional pausing. The mechanism ofthis phenom-
enon is not clear. One possibility is that atranscriptional
pausing signal in exon 1 couldblock RNApolymerase II
progression through the gene. Infact, poly T sequences,
which block RNA polymerase III in Xenopus 5S RNA
genes, are found in human c-myc exon 1(68). The impor-
tance of the block in elongation in regulating c-myc
mRNA levels was demonstrated by thefinding that the
decrease in c-myc mRNA in differentiating HL-60 cells
is due to anincrease inthe degree ofblock(68). Marcu has
extended thesefindings and demonstratedthat transcrip-
tional pausing ofc-myc transcription occurs in many cell
lines (69). Transcriptional pausingis notunique to c-myc,
as Bender et al. has described a similar effect on c-myb
gene transcription (70). It is conceivable that regulation
by transcriptional pausing may provide a rapid mecha-
nism ofcontrollingthe expression ofthese importantreg-
ulatory genes (71).
In addition to transcriptional controls myc mRNA
levels also appear to be regulatedbyposttranscriptional
events. Forexample, the large decrease inc-myc mRNA
that occurs when Daudi cells are treated with P interfe-
ronisunaccompanied by changes in c-mycgenetranscrip-
tion (72). Also, the decrease in c-myc mRNA that occurs
in differentiating F9 cells, appears to be posttranscrip-
tional(73). However, the discoveryoftranscriptional paus-
ing casts some doubt onprevious attempts tomeasure c-
myc gene transcription using DNA probes that contain
the entire c-myc gene.
Inorderto determinewhetherthe changesinc-myc ex-
pression in differentiated MEL cells are due totranscrip-
tional orposttranscriptional events, we measured c-myc
gene transcriptionusing an invitro nuclearrun on assay.
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Multiple single-stranded segments of the c-myc gene
were used as probes for in vitro labeled RNA, to deter-
mine whether transcriptional pausing occurs in MEL
cells. In addition, single-strandedprobes-ofthe antisense
strand were also used in order to detect antisense RNA
transcription. We included this in the analysis because
Marcu had detected significant myc antisense transcrip-
tion in many cell lines (74). Our transcriptional analysis
revealed that similar to other cells, MEL cells transcribe
thefirst exonmore efficiently thanexons2and3. Further,
when the cells are treated with HMBA, there is an in-
crease in transcriptional pausing, resulting in a dramatic
decrease ineffective c-myc transcription; aphenomenon
that can be detected as early as 20 min following the ad-
dition ofinducers (75). Thus, the early decrease in c-myc
mRNA that occurs following exposure to inducers is ini-
tiated by a block in c-myc transcript elongation, similar
to HL-60 cells. However, after 2 hr ofHMBAtreatment,
effective transcription returns tothe level found in unin-
duced MEL cells, yet c-myc mRNA levels remain quite
low. This suggests that although the early decrease in c-
myc mRNA is initiated by an increase in transcriptional
pausing, the maintenance of the decrease is posttran-
scriptional. Furthermore, the 10-fold increase in c-myc
mRNAlevels between 12 and24 hr ofinducertreatment
and the second decline which occurs as the cells termi-
nally differentiate, are also notassociatedwith significant
changes in effective transcription, indicating that these
changes in c-myc mRNA are due to posttranscriptional
events (Fig. 5). In our experiments we also detected sig-
nificant myc antisense transcription. However, the
changes in c-myc mRNA could not be correlated with
fluctuations in antisense transcription (75).
Posttranscriptional regulation is ageneral term imply-
ing regulation at the level of nuclear RNA processing,
transport ormRNA stability. Experimental approaches
to distinguish between these possibilities are limited by
our lack of understanding of mRNA transport and the
instability ofprecursor RNAs. Recent work concerning
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the regulation oftubulin mRNA demonstrates that bar-
riers to the understanding ofposttranscriptional regula-
tion are beinglifted byimproved experimental strategies
(76).
In the case ofc-myc mRNA, we focused on the possi-
bility that mRNA stability could be a factor in regulat-
ing c-myc expression because several authors have sug-
gested that the c-myc mRNA levels in other cell lines
couldbe regulated at this level (77,78). The halflife(TI/2)
ofc-myc mRNA in uninduced MEL cells was measured
using an actinomycin D chase protocol in which the disap-
pearance of an mRNA from the cell, which occurs at a
rate proportional to itsintrinsicT1/2, is measuredfollow-
ing actinomycin D-induced transcription inhibition. Using
this approach, we obtained a value of 13 min, indicating
that the mRNA is quite unstable in these cells. Since
treatment ofMEL cellswith HMBAresultsinthe virtual
disappearance of c-myc mRNA we could not directly
measure the T112 of c-myc mRNA at those times.
However, several experiments indicated to us that the
mRNA is not more unstable during HMBA treatment.
First, the decrease in c-myc mRNA in the first 2 hr of
HMBA treatment occurs with a rate ofdecay of 10 min,
similar to the actual T112 of c-myc mRNA in uninduced
cells. Since effective c-myc transcription duringthis time
is only 5% thelevelfoundinuninduced cells, avalue simi-
lartothe degree ofinhibition ofeffective c-myctranscrip-
tion resulting from actinomycin D treatment, the rate of
the decrease inc-mycmRNAduringthistimeapproaches
the actual T1/2.
Second, we measuredthe T1/2 ofc-myc mRNA during
its reexpression between 12 and 24 hr of HMBA treat-
ment and obtained theidentical value of13min we found
in uninduced cells. Third, we measured the T1/2 ofa chi-
meric MT-myc mRNA that is reexpressed during the
timethatendogenous c-mycmRNAisquitelow. TheT1/2
of MT-myc mRNA was not significantly different from
that found in uninduced cells, demonstrating that during
the time when c-myc mRNAlevels are decreased, amyc
L
FIGURE 5. Demonstration ofce-myc transcriptional pausing in MEL cells Single-stranded probes for the noncodingfirst exon(A) and the coding exons
(B)wereprepared fromM13 subelones andslotted ontonitrocellulose filters. GAPDH is acontrolgene whose expression varieslittle duringinducer
treatment while mplO is anegative control. After20min, transcription into the coding exonsmarkedly decreases, whereas transcription in exon
1 is constitutive, indicating ablock intranscriptional elongation. By 2hr, the rate oftranscription into the coding exons has returned to the level
found in uninduced cells. Note that in uninduced cells there is also adegree ofblock. This is seen more easily in the 0 time points corresponding
to theexperiments inwhichtranscription wasmeasuredbetween 2-20hrand at 48and60hr. Theintensity oftheprobe Asignal underestimates
the actual transcription rate compared with probe B because probe B contains 5 times more labeling sites than probe A.
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containing mRNA can be detected whose stability is un-
affected by inducer treatment (unpublished observations).
These data indicate that the stability of c-myc is un-
changed during inducer treatment and suggests that
posttranscriptional regulationof c-mycmRNAin inducer-
treated cells occurs at a nuclear level, such as RNA
processing or transport (75).
There have been two other reports that suggested that
the changes in c-myc mRNAlevels in MEL cells are due
to transcriptional events and changes in mRNA stability
(79,80). In both reports, gene transcription was only mea-
sured early in inducer treatment, thus the return in ef-
fective transcription we detected after 2 hr of HMBA
treatment was not observed. By not measuring c-myc
gene transcription laterinthe differentiationpathway, the
transcriptional component ofits regulation was overem-
phasized. The role of c-mycmRNA stability in one ofthe
reports was based on only one time point on a Northern
filter hybridization of RNA from actinomycin D-treated
cells, which makes these data difficult to interpret (79).
Nevertheless, it is conceivable that different isolates of
MEL cells could regulate myc mRNA differently.
Mechanism of Nuclear
Posttranscriptional Regulation
In order to understand the mechanism of nuclear
posttranscriptional regulation, we have begun to study
the expression of chimeric myc genes in differentiating
MEL cells. As mentioned earlier, a chimeric myc mRNA
containingthe myc coding exons andmetallothionein-1 se-
quences (MT-myc)undergoes biphasic changes in inducer-
treated cells similar to endogenous c-myc mRNA. Using
in vitro nuclear run analysis we determnined that the early
decrease in MT-myc mRNA was posttranscriptional (un-
publishedobservations). Transcriptional pausingis not ob-
served with MT-myc because the chimeric gene does not
contain the exon I sequences where pausing has been
mapped. We also found that the earlyreexpression ofMT-
myc mRNAbetween 4 and 8 hr ofHMBAtreatment was
due to alarge 5- to 10-fold increase inMT-myc transcrip-
tion. However, the finding that MT-myc mRNA levels in
4 to 8 hr HMBA-treated cells is similar to the level found
inuninduced cells, despite the large increase intranscrip-
tion, suggests that similar to c-myc, posttranscriptional
events are affecting MT-myc mRNA levels throughout
the differentiation process. Measurements of chimeric
MT-myc T1/2 using actinomycin D revealed that changes
in mRNA stability could not account for the posttran-
scriptional changes in the mRNA. These findings suggest
that similar to c-myc mRNA, the levels of MT-myc
mRNA appeared to be regulated at a nuclear posttran-
scriptional level. The data also imply that the sequences
responsible for nuclear posttranscriptional regulation
could be contained within the 1.36 kb Xho fragment,
which includes the c-myc coding exons, the only se-
quences common to c-myc and MT-myc.
An alternative explanation is that a regulatory event
common to both mRNAs is being affected. For example,
c-myc mRNAs and MT-myc mRNAs are both spliced, c-
myc at itsnormal splice donorandacceptor sites, and MT-
myc within residual MT sequences in the 3' end ofMT-
myc RNA. MT-myc does not contain myc splice sites,
since the myc containing sequences were derivedfrom a
cDNA clone.
In order to determine whether a splicing defectinduced
by HMBA treatment could be involved in nuclear post-
transcriptional regulation, we transfected MEL cells with
an intronless chimeric myc gene we constructed called
CLAHX3-myc, which also contains the 1.36 myc Xho
fragment. We found that expression of CLAHX3-myc
mRNAundergoes the samebiphasic changes in differen-
tiatingMEL cells as c-myc andMT-myc mRNAs demon-
stratingthat the absence ofintrons does notprevent the
biphasic change in myc-containing mRNAs from occur-
ring. The data also lendsfurther supportto the hypothe-
sis that the 1.36 kb Xhol fragment is involved in regulat-
ing myc mRNA levels, possibly at the level of RNA
transport. Our results with a variety ofmyc expression
vectors are in contrast to the findings ofthe groups who
have been able to obtain clones ofMEL cells that consti-
tutively express chimeric mycgenes duringinducertreat-
ment (64-66). There is not an adequate explanation for
these differences, especially without data concerningthe
transcription rates ofthe other chimeric mycgenes. It is
conceivable that an increase in transcription sufficient to
overcome nuclearposttranscriptional regulation could ac-
count forthe ability ofsome ofthese chimericmycgenes
to be expressed duringinducer treatment. Alternatively
differences in DNA copy numberorgenomicintegration
sites could be a factor.
In summary, the regulation ofc-mycmRNAis a rather
complex mixture of transcriptional and posttranscrip-
tional events. A new concept to the understanding ofmyc
regulation is the idea that the myc coding sequences may
be adeterminantinregulatingmycmRNAlevelsthrough
a poorly defined nuclear posttranscriptional process.
Role of c-myc Expression in MEL
Cell Differentiation
Althoughthe function ofthe protein encodedby c-myc
is not known, it appears to play a significant role in cell
growth. Forexample, followingtreatment ofresting cells
with mitogens orgrowthfactors, there is alarge increase
in c-myc expression that precedes the cells' entry into S
phase (77). Treatment ofisolated nuclei with antibodies
to mycprotein, orT-lymphocytes and HL-60 cells with c-
myc antisense oligonucleotide, inhibits DNA synthesis
(82,83). The antisense sequence inhibitsmycprotein syn-
thesis, presumablybyforming an RNA:RNAhybridwith
complementary nucleotides inmycmRNA, preventing its
translation. Also, transfection of3T3 cells with an indu-
cible myc chimeric gene results in a partial reduction in
the requirement for platelet-derived growth factor
(PDGF) to stimulate cell division (84). Finally, an inap-
propriate growth signal by abnormally regulated myc se-
quences translocated intoimmunoglobulinloci appears to
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be amajorfactorin thepathogenesis ofhuman Burkitt's
lymphoma and murine plasmacytoma (85,86).
There is also some evidence, although less convincing,
that c-mycprotein affects gene expression. The mycgene
hasbeenfoundtoincreasetranscription fromaheatshock
gene promoter (hsp 70) and to decrease metallothionein
(MT) 1 gene expression in atransient expression system
(87). Ofinterest is that the inhibitory effect ofmyc pro-
teins on MT-1 expression is abolished by mutations in
exon 2, whereas hsp 70activation isnotaffected, suggest-
ingthatthe inhibitingandactivating domains are encoded
by different sequences. In some cells expression ofmyc
or myc-related transfected genes appears to downregu-
late endogenous myc (88). It isbelieved thatmycprotein
could interfere with myc gene regulatory elements by
negative feedback inhibition (89). However, so far, there
is no direct proofthatthis occurs. Certainly, in MEL cells
we andothershave notdetectedanyevidencethatexpres-
sion of transfected myc genes suppresses endogenous
c-myc.
Despite the relative dearth ofevidence thatmyc regu-
lates gene expression, the effect of transfected myc se-
quences on MEL cell differentiation is most easily ex-
plained by a role in gene expression. The DNA
transfection experiments point to two different effects of
myc expression. First, the findingthat constitutive myc
expression during inducer treatment inhibits differenti-
ation(64-66)suggeststhatmycinhibits asubset ofgenes,
which are designated group 1 and are activated during
the early inducer-mediated decline in c-myc expression.
These genes are inhibited in uninduced cells as a result
of constitutive myc expression. Perhaps during normal
erythroid differentiation there is a signal that results in
rapid c-myc downregulation whichtriggers group 1 gene
activation. However, viral transformation may prevent
MEL cells from differentiating by delivering an inap-
propriate growth signal, the consequence ofwhich is con-
stitutive myc expression and group 1 gene suppression.
Inducing agents of differentiation may be capable of
bypassing the viral activation ofc-myc to induce an early
decline in itsexpressionbyinitiating ablockintranscrip-
tional elongation and activating nuclear posttranscrip-
tional controls on c-myc gene expression. As a conse-
quence of this series of events, c-myc is downregulated
and group 1 genes are activated (Fig. 6).
The activation ofputative group 1 genes appears to be
insufficient for commitment to occur. If MEL cells are
plated in the absence ofinducerafter 12 hr oftreatment,
a time which includes the entire period of the c-myc
mRNA decline, few, ifany cells are committed to differen-
tiate. Clearly, other events must occur in orderfor MEL
cells to become committed.
The data from our MT-myc transfection experiment
suggestthat mycreexpression alsoplays arole inregulat-
ing commitment. The timing of myc reexpression in
parental cells coincideswiththeability to detect commit-
ted cells, and rapid reexpression ofMT-myc or c-myc is
associated with an increase in the rate cells become com-
mitted. The model most consistent with this picture is
thatthere is a subset ofgenes(group2)that are activated
Committed
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FIGURE 6. Hypothesis for the role of c-myc in generating committed
cells. As a result ofFriend virus transformation, MEL cells receive
a constitutive growth signal, the consequence of which is the
constitutive expression ofc-myc (A). Following inducertreatment, c-
myc expression decreases, activatinggroup 1 genes which had been
previously inhibited bymyc. Duringthe reexpression ofmyc, which
occursprimarily in G1 cells, group 2genes, dependent on inducerplus
myc reexpression, are activated. The combination of group 1 and
group 2 gene expression drives the cell into a commitment program.
because ofmyc reexpression. The activation ofgroup 2
genes maybe acell-cycle-mediated event, sincemycreex-
pression occurs primarily in G, cells. Since the timing of
myc reexpression depends on a cell's position in the cell
cycle when first exposed to an inducer, one may expect
group 2 genes to become activated at different times in
an asynchronous population of cells, an assumption that
could explain why MEL cells become committed at dif-
ferentrates. The combination ofgroup 1 and group 2 gene
expression is needed for cells to enter a commitmentpro-
gram (Fig. 6).
The ability ofmyc to influence bothreplication and cel-
lular differentiation is consistent with the model of the
gene as amultipurpose regulatory molecule. In this way
itisanalogous tothe adenovirus EIAgenethatinfluences
viral replication andhasbothinhibitory and activatingef-
fects on cellular gene expression (90,91). The functional
analogy between myc and EIA is also demonstrated by
the finding that EIA can substitute for myc in the
cotransformation ofprimaryfibroblastswith an activated
ras gene (92,93).
Although this paper has focused on the c-myc gene, it
is not the only protooncogene involved in MEL cell
differentiation. Itis only one ofatleastfournuclearpro-
tooncogenesthat are expressedinMEL cells. Indeed, the
pattern of expression of other nuclear protooncogenes
such as c-fos, c-myb and p53 suggests that these genes
could also be involved in regulating the differentiation
process. For example c-fos mRNAincreases 5- to 10-fold
within 2 to 4 hr of inducer treatment, p53 expression
decreases approximately 20-fold (unpublished observa-
tions), and c-myb undergoes biphasic changes, similar to
c-myc mRNA (80). The importance of these changes in
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the commitmentprogram isbeinginvestigatedby several
groups.
Because of the unusual nature of c-myc expression in
differentiating MEL cells, the system provides a unique
opportunity to understand the physiological role and reg-
ulation ofc-myc in cells. By applying recombinant DNA
strategies in studying the c-myc gene, we hope to under-
stand the basis ofmalignant transformation ofleukemia
cells and the ability ofthese cells to terminally differen-
tiate in vitro.
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